Unraveling the Amyloid Enigma: Reframing Alzheimer’s Narratives in a New Era of Biomarkers and Lifestyle Interventions
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgmZk1DzgRC9M0YZ-b8Ginxk6RlfNUf36T_FNnVIc-oUyB6kHErh5whnOyitHAgVzOmriehPB8w1IQZ_02KDw4pzptPY6svE2yYWd8QOvcyifXUhr6QzyD-UrRc1IDQzw3p_0o0rcjzhr-ptijQ7LxXmQ-YDKIl6F46uNNa7V82sc-7EOTDqMw4dvKpcNX1/w608-h344/memory-loss-dementia-alzheimer-concept-created-with-generative-ai-technology.jpg)
From AAIC Amsterdam: A Renewed Emphasis on Amyloid and a Fresh Look at Disease Staging in Alzheimer’s Research Interesting times at the Alzheimer’s Association International Conference (AAIC) in Amsterdam last week. Some positive findings with amyloid lowering drugs in early stages of Alzheimer’s were welcomed and seem to have led to the launch of a new 7 part staging process to measure the disease. This should amuse the researchers at New York University who published the Global Deterioration Scale back in 1988. This was used commonly at first, especially in clinical trials, but drifted out of use. But now something broadly similar is back, this time bolstered by the inclusion of biomarkers. In fact there is a stage A0, which is biomarker change, but no symptoms. Amyloid: Biomarker, Warning Sign, or Both? Delving Into the Implications for Alzheimer’s Disease Prognosis and Early Detection This starts to raise questions. It is known that amyloid accumulation affects tau proteins a...